NCT06506994View on ClinicalTrials.gov

A Study of HRS-9057 in Patients With Heart Failure and Volume Overload

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

September 20, 2024

Study Completion Date

October 20, 2024

Conditions
Heart Failure With Volume Overload
Interventions
DRUG

HRS-9057

HRS-9057 injection dose 1

DRUG

HRS-9057

HRS-9057 injection dose 2

DRUG

Tolvaptan

Tolvaptan tablets

Trial Locations (1)

510285

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY

NCT06506994 - A Study of HRS-9057 in Patients With Heart Failure and Volume Overload | Biotech Hunter | Biotech Hunter